Oncolytic herpes simplex virus kills stem-like tumor-initiating colon cancer cells

Molecular Therapy Oncolytics

Volumn 3, Issue , 2016, Pages 16013-

  Warner, Susanne G ^a   Haddad, Dana ^b   Au, Joyce ^c   Carson, Joshua S ^d   O'Leary, Michael P ^a   Lewis, Christina ^e   Monette, Sebastien ^b   Fong, Yuman ^a  

^a Department of Surgery ^*  (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NV 1066; ONCOLYTIC HERPES VIRUS; PROTEIN AKT1; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CANCER SIZE; CANCER STEM CELL; CARCINOGENICITY; CELL KILLING; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; GENE OVEREXPRESSION; GROWTH RATE; HERPES SIMPLEX VIRUS 1; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR INITIATING CELL; VIRUS REPLICATION;

EID: 85006201097     PISSN: None     EISSN: 23727705     Source Type: Journal    
DOI: 10.1038/mto.2016.13     Document Type: Article

References (60)

1. Clarke, MF, Dick, JE, Dirks, PB, Eaves, CJ, Jamieson, CH, Jones, DL et al. (2006). Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344.
2. Dingli, D and Michor, F (2006). Successful therapy must eradicate cancer stem cells. Stem Cells 24: 2603-2610.
3. Ribacka, C and Hemminki, A (2008). Virotherapy as an approach against cancer stem cells. Curr Gene Ther 8: 88-96.
4. Hill RP. Identifying cancer stem cells in solid tumors: case not proven. Cancer Res 2006;66:1891-1895; discussion 1890.
5. Woodward, WA and Sulman, EP (2008). Cancer stem cells: markers or biomarkers? Cancer Metastasis Rev 27: 459-470.
6. Croker, AK and Allan, AL (2008). Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 12: 374-390.
7. Chu, P, Clanton, DJ, Snipas, TS, Lee, J, Mitchell, E, Nguyen, ML et al. (2009). Characterization of a subpopulation of colon cancer cells with stem cell-like properties. Int J Cancer 124: 1312-1321.
8. Dou, J and Gu, N (2010). Emerging strategies for the identification and targeting of cancer stem cells. Tumour Biol 31: 243-253.
9. Dean, M (2009). ABC transporters, drug resistance, cancer stem cells. J Mammary Gland Biol Neoplasia 14: 3-9.
10. Gou, S, Liu, T, Wang, C, Yin, T, Li, K, Yang, M et al. (2007). Establishment of clonal colonyforming assay for propagation of pancreatic cancer cells with stem cell properties. Pancreas 34: 429-435.
11. Vermeulen L, Todaro M, de Sousa Mello F, et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA 2008;105:13427-13432.
12. Hamburger, AW and Salmon, SE (1977). Primary bioassay of human tumor stem cells. Science 197: 461-463.
13. Spillane, JB and Henderson, MA (2007). Cancer stem cells: a review. ANZ J Surg 77: 464-468.
14. Singh, SK, Hawkins, C, Clarke, ID, Squire, JA, Bayani, J, Hide, T et al. (2004). Identification of human brain tumour initiating cells. Nature 432: 396-401.
15. Zito, G, Richiusa, P, Bommarito, A, Carissimi, E, Russo, L, Coppola, A et al. (2008). In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One 3: e3544.
16. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007;104:973-978.
17. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100: 3983-3988.
18. Ho, MM, Ng, AV, Lam, S and Hung, JY (2007). Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67: 4827-4833.
19. Kim, CF, Jackson, EL, Woolfenden, AE, Lawrence, S, Babar, I, Vogel, S et al. (2005). Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121: 823-835.
20. Huang, D, Gao, Q, Guo, L, Zhang, C, Jiang, W, Li, H et al. (2009). Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev 18: 465-473.
21. Hermann, PC, Huber, SL, Herrler, T, Aicher, A, Ellwart, JW, Guba, M et al. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323.
22. O'Brien, CA, Pollett, A, Gallinger, S and Dick, JE (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
23. Ricci-Vitiani, L, Lombardi, DG, Pilozzi, E, Biffoni, M, Todaro, M, Peschle, C et al. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
24. Bapat, SA, Mali, AM, Koppikar, CB and Kurrey, NK (2005). Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65: 3025-3029.
25. Schatton, T, Murphy, GF, Frank, NY, Yamaura, K, Waaga-Gasser, AM, Gasser, M et al. (2008). Identification of cells initiating human melanomas. Nature 451: 345-349.
26. Zucchi I, Sanzone S, Astigiano S, et al. The properties of a mammary gland cancer stem cell. Proc Natl Acad Sci USA 2007;104:10476-10481.
27. Carracedo, A and Pandolfi, PP (2008). The PTEN-PI3K pathway: of feedbacks and crosstalks. Oncogene 27: 5527-5541.
28. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. WNT/betacatenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 2007;104:618-623.
29. Eyler, CE, Foo, WC, LaFiura, KM, McLendon, RE, Hjelmeland, AB and Rich, JN (2008). Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells 26: 3027-3036.
30. Shinozaki, K, Ebert, O and Woo, SL (2005). Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology 41: 196-203.
31. Fong, Y, Kim, T, Bhargava, A, Schwartz, L, Brown, K, Brody, L et al. (2009). A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther 17: 389-394.
32. Cripe, TP, Wang, PY, Marcato, P, Mahller, YY and Lee, PW (2009). Targeting cancer-initiating cells with oncolytic viruses. Mol Ther 17: 1677-1682.
33. Coukos, G, Makrigiannakis, A, Kang, EH, Rubin, SC, Albelda, SM and Molnar-Kimber, KL (2000). Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res 6: 3342-3353.
34. Zhang, X, Komaki, R, Wang, L, Fang, B and Chang, JY (2008). Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res 14: 2813-2823.
35. Adusumilli, PS, Stiles, BM, Chan, MK, Eisenberg, DP, Yu, Z, Stanziale, SF et al. (2006). Realtime diagnostic imaging of tumors and metastases by use of a replication-competent herpes vector to facilitate minimally invasive oncological surgery. FASEB J 20: 726-728.
36. Reinblatt, M, Pin, RH and Fong, Y (2007). Herpes viral oncolysis: a novel cancer therapy. J Am Coll Surg 205(4 Suppl): S69-S75.
37. Kemeny, N, Brown, K, Covey, A, Kim, T, Bhargava, A, Brody, L et al. (2006). Phase I, openlabel, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 17: 1214-1224.
38. Markert, JM, Medlock, MD, Rabkin, SD, Gillespie, GY, Todo, T, Hunter, WD et al. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867-874.
39. Rampling, R, Cruickshank, G, Papanastassiou, V, Nicoll, J, Hadley, D, Brennan, D et al. (2000). Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7: 859-866.
40. Senzer, NN, Kaufman, HL, Amatruda, T, Nemunaitis, M, Reid, T, Daniels, G et al. (2009). Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27: 5763-5771.
41. Nagano, S, Perentes, JY, Jain, RK and Boucher, Y (2008). Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res 68: 3795-3802.
42. Harrow, S, Papanastassiou, V, Harland, J, Mabbs, R, Petty, R, Fraser, M et al. (2004). HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 11: 1648-1658.
43. Stanziale, SF, Petrowsky, H, Adusumilli, PS, Ben-Porat, L, Gonen, M and Fong, Y (2004). Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity. Clin Cancer Res 10: 3225-3232.
44. Mahller, YY, Williams, JP, Baird, WH, Mitton, B, Grossheim, J, Saeki, Y et al. (2009). Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One 4: e4235.
45. Wakimoto, H, Kesari, S, Farrell, CJ, Curry, WT Jr, Zaupa, C, Aghi, M et al. (2009). Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 69: 3472-3481.
46. Smith, TT, Roth, JC, Friedman, GK and Gillespie, GY (2014). Oncolytic viral therapy: targeting cancer stem cells. Oncolytic Virother 2014: 21-33.
47. Zeelenberg, IS, Ruuls-Van Stalle, L and Roos, E (2003). The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 63: 3833-3839.
48. Gassmann, P, Haier, J, Schluter, K, Domikowsky, B, Wendel, C, Wiesner, U et al. (2009). CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neoplasia 11: 651-661.
49. Saigusa, S, Tanaka, K, Toiyama, Y, Yokoe, T, Okugawa, Y, Ioue, Y et al. (2009). Correlation of CD133, OCT4, SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 16: 3488-3498.
50. Horst, D, Scheel, SK, Liebmann, S, Neumann, J, Maatz, S, Kirchner, T et al. (2009). The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 219: 427-434.
51. Dick JE. Breast cancer stem cells revealed. Proc Natl Acad Sci USA 2003;100:3547-3549.
52. Kooby, DA, Carew, JF, Halterman, MW, Mack, JE, Bertino, JR, Blumgart, LH et al. (1999). Oncolytic viral therapy for human colorectal cancer and liver metastases using a multimutated herpes simplex virus type-1 (G207). FASEB J 13: 1325-1334.
53. Cassady, KA, Gross, M and Roizman, B (1998). The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha. J Virol 72: 7005-7011.
54. Chou J, Roizman B. The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc Natl Acad Sci USA 1992;89:3266-3270.
55. Chou J, Chen JJ, Gross M, Roizman B. Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5-mutants of herpes simplex virus 1. Proc Natl Acad Sci USA 1995;92:10516-10520.
56. He, B, Chou, J, Brandimarti, R, Mohr, I, Gluzman, Y and Roizman, B (1997). Suppression of the phenotype of gamma(1)34.5-herpes simplex virus 1: failure of activated RNAdependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol 71: 6049-6054.
57. MacLeod, IJ and Minson, T (2010). Binding of herpes simplex virus type-1 virions leads to the induction of intracellular signalling in the absence of virus entry. PLoS One 5: e9560.
58. Galvan, V, Brandimarti, R and Roizman, B (1999). Herpes simplex virus 1 blocks caspase-3-independent and caspase-dependent pathways to cell death. J Virol 73: 3219-3226.
59. Kang, JQ, Chong, ZZ and Maiese, K (2003). Critical role for Akt1 in the modulation of apoptotic phosphatidylserine exposure and microglial activation. Mol Pharmacol 64: 557-569.
60. Wong, RJ, Joe, JK, Kim, SH, Shah, JP, Horsburgh, B and Fong, Y (2002). Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther 13: 1213-1223.